SNGX - Soligenix, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
1.66
-0.05 (-2.92%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close1.71
Open1.74
Bid1.66 x 6000
Ask2.00 x 1000
Day's Range1.60 - 1.74
52 Week Range1.60 - 3.90
Volume77,647
Avg. Volume154,777
Market Cap14.51M
Beta-0.14
PE Ratio (TTM)N/A
EPS (TTM)-1.16
Earnings DateMay 9, 2018 - May 14, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est3.85
Trade prices are not sourced from all markets
  • PR Newswirelast month

    Soligenix Receives Orphan Drug Designation from the European Commission for RiVax® for Prevention of Ricin Poisoning

    PRINCETON, N.J., March 22, 2018 /PRNewswire/ -- Soligenix, Inc. (SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that the European Commission, acting on the positive recommendation from the European Medicines Agency (EMA) Committee for Orphan Medicinal Products, has granted orphan drug designation to the Company's recombinant modified ricin toxin A-chain subunit (the active pharmaceutical ingredient in RiVax®) for the prevention of ricin poisoning.  RiVax® has previously been granted orphan drug designation from the US Food and Drug Administration (FDA).

  • PR Newswirelast month

    Soligenix Announces Recent Accomplishments And Year-End 2017 Financial Results

    PRINCETON, N.J., March 15, 2018 /PRNewswire/ -- Soligenix, Inc. (SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today its recent accomplishments and financial results for the year ended December 31, 2017. Christopher J. Schaber, PhD, President and Chief Executive Officer of Soligenix stated, "In the third quarter of 2017, we initiated a pivotal double-blind, placebo-controlled Phase 3 clinical trial of SGX942 (dusquetide) for the treatment of oral mucositis in patients with head and neck cancer receiving chemoradiation therapy.

  • PR Newswirelast month

    Soligenix to Present at the 12th Annual International Partnering Conference Bio-Europe Spring

    PRINCETON, N.J., March 13, 2018 /PRNewswire/ -- Soligenix, Inc. (SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that its Chief Financial Officer, Karen Krumeich, will deliver a corporate presentation at the 12th Annual International Partnering Conference Bio-Europe Spring in Amsterdam, Wednesday, March 14 at 10:00 AM GMT. For more information about the 12th Annual International Partnering Conference Bio-Europe Spring, please refer to the conference website.

  • PR Newswire3 months ago

    Soligenix - Driving Towards Key Inflection Points with Two Pivotal Phase 3 Clinical Trials

    PRINCETON, N.J., Jan. 25, 2018 /PRNewswire/ -- Soligenix, Inc. (SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, today issued an update letter from its President and Chief Executive Officer, Dr. Christopher J. Schaber.  The content of this letter is provided below.

  • ACCESSWIRE4 months ago

    Blog Exposure - Soligenix Announced Issuance of US Patent for Use of Dusquetide in Oral Mucositis

    LONDON, UK / ACCESSWIRE / January 04, 2018 / Active-Investors.com has just released a free research report on Soligenix, Inc. (NASDAQ: SNGX ). If you want access to this report all you need to do is sign ...

  • PR Newswire4 months ago

    Soligenix Announces US Patent Issuance for Use of Dusquetide in Oral Mucositis

    Soligenix has reported positive Phase 2 results with SGX942 in the treatment of oral mucositis in head and neck cancer (HNC) patients.  SGX942 at a dose of 1.5 mg/kg successfully reduced the median duration of severe oral mucositis by 50% in all patients and by 67% in patients receiving the most aggressive chemoradiation therapy for treatment of their HNC.  In addition to the oral mucositis findings, an increased incidence of "complete response" of tumor at both the one month and twelve month follow-up visits were observed with SGX942 treatment, as well as decreases in mortality and infection rate.  Results from the Phase 2 clinical trial have been published.

  • Zacks Small Cap Research4 months ago

    Soligenix (SNGX): Identifies Biomarkers for Ricin Toxin Vaccine Testing under the FDA Animal Rule

    On Dec. 21, 2017, SNGX (SNGX) announced the successful identification of biomarkers for ricin toxin vaccine (RiVax®) testing. This could facilitate the approval of the testing under the FDA "Animal Rule".

  • PR Newswire4 months ago

    Soligenix Identifies Biomarkers for Ricin Toxin Vaccine Testing under the FDA Animal Rule

    PRINCETON, N.J. , Dec. 21, 2017 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat ...

  • Want To Invest In Soligenix Inc (SNGX)? Here’s How It Performed Lately
    Simply Wall St.5 months ago

    Want To Invest In Soligenix Inc (SNGX)? Here’s How It Performed Lately

    After looking at Soligenix Inc’s (NASDAQ:SNGX) latest earnings update (30 September 2017), I found it helpful to revisit the company’s performance in the past couple of years and compare thisRead More...

  • PR Newswire5 months ago

    Soligenix to Receive $417,000 in Non-Dilutive Funding Through New Jersey Technology Business Tax Certificate Transfer Program

    PRINCETON, N.J., Nov. 30, 2017 /PRNewswire/ -- Soligenix, Inc. (SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that it has received preliminary approval for a tax credit from the New Jersey Economic Development Authority's (NJEDA) New Jersey Technology Business Tax Certificate Transfer program.  As a result, the Company anticipates being able to transfer this credit and receive approximately $417,000 in net proceeds by year end. This competitive program enables approved technology and biotechnology businesses to sell their unused Net Operating Loss (NOL) Carryovers and unused Research and Development (R&D) Tax Credits to unaffiliated, profitable corporate taxpayers in the state of New Jersey.

  • PR Newswire5 months ago

    Soligenix Announces Presentation and Poster at the 2017 Chemical and Biological Defense Science and Technology Conference in Long Beach, CA

    PRINCETON, N.J., Nov. 27, 2017 /PRNewswire/ -- Soligenix, Inc. (SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that Dr. Oreola Donini, Chief Scientific Officer, will be presenting preclinical data from two of its biodefense development programs at the upcoming Chemical and Biological Defense Science and Technology Conference on November 28-30, 2017 to be held at the Long Beach Convention Center, Long Beach, CA. The abstract is available here.

  • Who Owns Most Of Soligenix Inc (SNGX)?
    Simply Wall St.5 months ago

    Who Owns Most Of Soligenix Inc (SNGX)?

    Today, I will be analyzing Soligenix Inc’s (NASDAQ:SNGX) recent ownership structure, an important but not-so-popular subject among individual investors. Ownership structure has been found to have an impact on shareholderRead More...

  • PR Newswire5 months ago

    Soligenix to Present at the 2017 Biotech and Money Showcase Conference

    PRINCETON, N.J., Nov. 13, 2017 /PRNewswire/ -- Soligenix, Inc. (SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that its President and Chief Executive Officer, Christopher J. Schaber, PhD, will deliver a corporate presentation at the 2017 Biotech & Money Investival Showcase in London, England, Tuesday, November 14, at 1:30 PM GMT. Dr. Schaber will also be participating in the Jeffries 2017 London Healthcare Conference on November 15-16, 2017, co-located at The Waldorf Hilton Hotel. For more information about the 2017 Biotech & Money Investival Showcase, please refer to the conference website here.

  • PR Newswire6 months ago

    Soligenix to Present Data on Dusquetide in Combating Antibiotic-Resistant Infections at the 2nd Annual Superbugs & Superdrugs USA Conference

    PRINCETON, N.J., Nov. 9, 2017 /PRNewswire/ -- Soligenix, Inc. (SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that Oreola Donini, PhD, Senior Vice President and Chief Scientific Officer of Soligenix, will present preclinical and clinical results on the use of dusquetide in the treatment of emerging and antibiotic resistant infectious diseases at Superbugs & Superdrugs USA.  The conference is being held in Iselin, New Jersey November 13-14, 2017. Innate Defense Regulators: Broad-Spectrum, Host-Directed Therapy for Antibiotic Resistant Disease presented by Dr. Oreola Donini, Chief Scientific Officer of Soligenix, on November 13, 2017 at 9:50 am Eastern Standard Time.  Conference details are available here.

  • Zacks Small Cap Research6 months ago

    SNGX: Balance Sheet Boosted by Recent Financings

    As of September 30, 2017, the Company's cash position was $5.0 million. On November 3, 2017, the company announced that it had closed a registered direct offering of 1,575,500 shares of common stock at a premium price of $2.00 per share and 982,000 shares of common stock at an above the market purchase price of $2.00 per share in a concurrent private placement. In September 2017, the National Institute of Dental and Craniofacial Research (NIDCR), part of the NIH, awarded the company a Small Business Innovation Research (SBIR) grant of approximately $1.5 million over two years to support the conduct of its Phase III, multinational, randomized, double-blind, placebo-controlled study evaluating SGX942 (dusquetide) as a treatment for severe oral mucositis in patients with head and neck cancer receiving chemoradiation therapy (CRT).

  • PR Newswire6 months ago

    Soligenix Announces Recent Accomplishments And Third Quarter 2017 Financial Results

    PRINCETON, N.J., Nov. 6, 2017 /PRNewswire/ -- Soligenix, Inc. (SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today its recent accomplishments and financial results for the third quarter ended September 30, 2017. Christopher J. Schaber, PhD, President and Chief Executive Officer of Soligenix stated, "We continue to advance our pivotal Phase 3 clinical trial of SGX942 for the treatment of oral mucositis in head and neck cancer, as well as our pivotal Phase 3 study in cutaneous T-cell lymphoma (CTCL) with SGX301.

  • PR Newswire6 months ago

    Soligenix Announces Closing of $5,115,000 Concurrent Registered Direct Offering and Private Placement of Common Stock Priced Above Market

    PRINCETON, N.J., Nov. 3, 2017 /PRNewswire/ -- Soligenix, Inc. (SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that it has closed a registered direct offering of 1,575,500 shares of common stock at a premium price of $2.00 per share and 982,000 shares of common stock at an above the market purchase price of $2.00 per share in a concurrent private placement. Gross proceeds to the Company from these offerings are approximately $5,115,000 before deducting placement agent fees and other estimated offering expenses payable by the Company.

  • PR Newswire6 months ago

    Soligenix Announces Pricing of $5,115,000 Concurrent Registered Direct Offering and Private Placement of Common Stock Priced Above Market

    PRINCETON, N.J., Oct. 31, 2017 /PRNewswire/ -- Soligenix, Inc. (SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced that it has entered into definitive agreements with investors for the purchase and sale of 1,575,500 shares of common stock at a price of $2.00 per share in a registered direct offering and 982,000 shares of common stock at a purchase price of $2.00 per share in a concurrent private placement. The gross proceeds of the offering will be approximately $5,115,000 before deducting placement agent discounts and other estimated offering expenses. The Company intends to use the net proceeds for working capital and other general corporate purposes.

  • PR Newswire6 months ago

    Broad-Spectrum Innate Defense Regulator Platform Technology to be Presented at the Peptide Therapeutics Foundation Symposium

    PRINCETON, N.J., Oct. 24, 2017 /PRNewswire/ -- Soligenix, Inc. (SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that it will be presenting the Innate Defense Regulator (IDR) technology platform and its potential utility in various therapeutic applications on October 27, 2017 at the Peptide Therapeutics Foundation Symposium taking place at the Salk Institute for Biological Studies, La Jolla, CA from October 26 - 27, 2017.  The presentation will address the IDR mechanism of action as well as the preclinical and clinical data obtained with the Company's lead IDR peptide, dusquetide.

  • PR Newswire6 months ago

    Soligenix to Present at the 3rd Annual Dawson James Small Cap Conference

    PRINCETON, N.J., Oct. 17, 2017 /PRNewswire/ -- Soligenix, Inc. (SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that its President and Chief Executive Officer, Christopher J. Schaber, PhD, will give a corporate presentation at the 3rd Annual Dawson James Small Cap Conference, Thursday, October 19, at 9:30 AM Eastern Daylight Time. The conference will take place at the Wyndham Grand Hotel in Jupiter, Florida. For more information about the Dawson James Small Cap Conference, please refer to the conference website at www.dawsonjames.com.

  • Is There Now An Opportunity In Soligenix Inc (SNGX)?
    Simply Wall St.6 months ago

    Is There Now An Opportunity In Soligenix Inc (SNGX)?

    Soligenix Inc (NASDAQ:SNGX), a biotechnology company based in United States, saw a decent share price growth in the teens level on the NasdaqCM over the last few months. As aRead More...

  • PR Newswire7 months ago

    Dusquetide Technology Platform to be Presented at the 2nd World Congress and Expo on Immunology

    PRINCETON, N.J., Oct. 5, 2017 /PRNewswire/ -- Soligenix, Inc. (SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that it will be presenting the dusquetide (SGX94) technology platform and its utility in various therapeutic applications on October 9, 2017 at the 2nd World Congress and Expo on Immunology taking place in Chicago, IL from October 9 - 11, 2017.  The presentation will discuss potential anti-inflammatory, tissue healing, anti-infective and anti-tumor action, including data from the recently completed Phase 2 trial in oral mucositis. Therapeutic Applications of Innate Immune Modulation presented by Dr. Oreola Donini, Chief Scientific Officer on October 9, 2017 at 3:25 pm Central Time.  The abstract is available here.

  • PR Newswire7 months ago

    Soligenix Announces $700,000 Subaward Supporting Development Collaboration on Thermostabilization of an Ebola Vaccine Candidate

    PRINCETON, N.J., Sept. 25, 2017 /PRNewswire/ -- Soligenix, Inc. (SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that Soligenix will be participating in a Research Project (R01) grant awarded to the University of Hawai'i at Manoa (UH Manoa) for the development of a thermostabilized Ebola vaccine, with Soligenix awarded funding of approximately $700,000 over 5 years. The most advanced Ebola vaccines involve the use of vesicular stomatitis virus (VSV) and adenovirus vectors – live, viral vectors which complicate the manufacturing, stability and storage requirements.  Dr. Lehrer's vaccine is based on highly purified recombinant protein antigens, circumventing many of these manufacturing difficulties.  Dr. Lehrer and HBI have developed a robust manufacturing process for the required proteins.  Thermostabilization may allow for a product that can avoid the need for cold-chain distribution and storage, yielding a vaccine ideal for use in both the developed and developing world.

  • Zacks Small Cap Research7 months ago

    Soligenix (SNGX): Two SBIR Grant Awarded Supporting Two Pivotal Phase III Trials

    On September 20, Soligenix (SNGX) announced that the National Institute of Dental and Craniofacial Research (NIDCR), part of the National Institutes of Health (NIH), has awarded Soligenix a Small Business Innovation Research (SBIR) grant of approximately $1.5 million over two years to support the conduct of its Phase III, multinational, randomized, double-blind, placebo-controlled study evaluating SGX942 (dusquetide) as a treatment for severe oral mucositis in patients with head and neck cancer receiving chemoradiation therapy (CRT).